Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial

被引：0
|
作者：
Chen, H. [1 ]
Hu, Y. [2 ]
Fan, Y. [3 ]
Wu, G. [4 ]
Cang, S. [5 ]
Yang, Y. [6 ]
Yang, N. [7 ]
Ma, R. [8 ]
Jing, G. [9 ]
Liu, A. [10 ]
Xu, X. [11 ]
Tang, S. [12 ]
Cheng, Y. [13 ]
Yu, Y. [14 ]
Wu, Y-L. [1 ]
机构：
[1] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp,Guangdong Acad Med Sc, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China
[2] Hubei Canc Hosp, Dept Thorac Oncol, Wuhan, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] Meizhou Peoples Hosp, Dept Oncol, Meizhou, Peoples R China
[5] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China
[6] Third Peoples Hosp Chendu, Dept Thorac Surg, Chengdu, Peoples R China
[7] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha, Peoples R China
[8] Liaoning Canc Hosp, Med Oncol, Dept Thorac Canc, Shenyang, Peoples R China
[9] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Oncol, Hohhot, Peoples R China
[10] Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Peoples R China
[11] Wuhan Univ, Dept Oncol, Renmin Hosp, Hubei Gen Hosp, Wuhan, Peoples R China
[12] First Peoples Hosp Neijiang, Dept Oncol, Neijiang, Peoples R China
[13] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China
[14] Harbin Med Univ, Dept Internal Med, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22P
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [32] COMPARISON OF EGFR-TKIS AND PEMETREXED FOR KOREAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Lee, J. H.
    Ryu, Y. J.
    Chun, E. M.
    Chang, J. H.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S90 - S90
  • [33] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [34] Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
    He, Zhen
    Yang, Xiuli
    Ma, Tianjiang
    Yang, Qiumin
    Zhang, Chenghui
    Chen, Yunfang
    Wang, Pengyuan
    D'Incecco, Armida
    Metro, Giulio
    Uematsu, Shugo
    Wang, Qiming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (08) : 1657 - +
  • [35] Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer a multicenter, randomized, phase II trial
    Scagliotti, GV
    Kortsik, C
    Dark, GG
    Price, A
    Manegold, C
    Rosell, R
    O'Brien, M
    Peterson, PM
    Castellano, D
    Selvaggi, G
    Novello, S
    Blatter, J
    Kayitalire, L
    Crino, L
    Paz-Ares, L
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 690 - 696
  • [36] Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Neubauer, MA
    Garfield, DH
    Kuerfler, PR
    Raju, RN
    Lindquist, DL
    Soo, EW
    Khan, M
    Boehm, KA
    Asmar, L
    LUNG CANCER, 2005, 47 (01) : 121 - 127
  • [37] Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: A single-center, single-arm, phase II trial
    Zhang, Hailiang
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [39] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [40] Stereotactic Body Radiotherapy Plus First-Line EGFR-TKIs for Patients with Advanced EGFR-Mutant Non -Small Cell Lung Cancer: A Meta -Analysis
    Yuan, Z.
    Tao, D.
    Zhou, W.
    Wu, Y. Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E85 - E85
12345